Trial Profile
A phase 3 study of gemcitabine and S-1 compared with gemcitabine monotherapy in patients with unresectable advanced pancreatic cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 16 Sep 2015 Status is changed from active no longer recruiting to completed as per full results are published in Journal cancer chemotherapy and pharmacology.
- 25 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 25 Feb 2012 Planned number of patients changed from 250 to 100 as reported by University Hospital Medical Information Network - Japan.